Mesoblast limited : FDA Clears Phase 3 Heart Failure Trial 4-traders (press release) Industries Ltd to commence a Phase 3 trial in patients with chronic congestive heart failure using Mesoblast's proprietary Mesenchymal Precursor Cells (MPCs). The IND was cleared by the FDA within the minimum 30-day period following submission, and ... |
